SITC

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Retrieved on: 
Tuesday, January 9, 2024
Tumor microenvironment, Immunotherapy, Food, Society, SITC, Neoplasm, FDA, Pharmaceutical industry

Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo.

Key Points: 
  • Pre-clinical data presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) demonstrates CRB-601 overcame tumor immune exclusion and enhanced the activity of immune checkpoint inhibitors in vivo.
  • The Company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
  • “CRB-601 blocked latent TGFβ activation and enhanced immune cell penetration into the tumor microenvironment in pre-clinical models.
  • We believe this mechanism of action is complimentary to the effects of anti PD(L)-1 therapy leading to enhanced combinatorial efficacy.

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Retrieved on: 
Monday, January 8, 2024
Report, Therapeutic index, Immunotherapy, Forecasting, IND, Inflammation, Therapy, Cancer, Society, Non-Hodgkin lymphoma, RDE, Patient, Finance, SITC, Pharmaceutical industry

WATERTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and outlined its strategic outlook and expected milestones for 2024.

Key Points: 
  • -  Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 -
    WATERTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and outlined its strategic outlook and expected milestones for 2024.
  • In 2024, Werewolf plans to report initial data from the Phase 1 clinical trial in the second quarter of 2024.
  • In 2024, Werewolf plans to:
    Present preclinical data from WTX-712 in the first half of 2024.
  • Present preclinical data demonstrating the potential of INDUKINE molecules for inflammatory diseases by the fourth quarter of 2024.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Giant, Melanoma, Werewolf, Book, Immunotherapy, SITC, Kidney cancer, Society, Therapy, Biopharmaceutical, Georgetown University Medical Center, Harvard Medical School, Committee, Pharmaceutical industry

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
  • “Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy.
  • I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules,” said Dan Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics.
  • He has published over 500 scientific and review articles, co-edited five books, and given over 800 lectures worldwide.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Research, Neurology, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Conference, Cure, IND, SAPPHIRE, Spinal muscular atrophy, Clinical trial, Obesity, Standard of care, Annual general meeting, Gongshi, Consequence, Myostatin, DRAGON, Webcast, MPH, Patient, Rock, SMN, SMA, Renal cell carcinoma, SITC, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Retrieved on: 
Thursday, January 4, 2024
Patient, Food, Acute leukemia, Neoplasm, Immunotherapy, PRAME, Amgen, IND, Collection, MRD, TCR, FDA, Antigen, HLA, Trial of the century, Society, Therapy, MDS, Infrared spectroscopy correlation table, Cancer, Disclosure, ASH, Annual general meeting, HCT, MAGE-C2, Syndrome, Poster, Safety, ALL, Acute myeloid leukemia, C2, AML, MAGE-A1, Food and Drug Administration, HPV16, SITC, Pharmaceutical industry

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2024 clinical pipeline plans and highlighted recent corporate achievements.

Key Points: 
  • Additionally, we submitted INDs for two additional TCRs in December and the 30-day review period with the FDA is ongoing.
  • Plans to complete Phase 1 dosing and report clinical and translational data in 2024, and two-year relapse data in 2025.
  • Initiated Phase 1 solid tumor clinical study and expects to dose the first patient in the first quarter of 2024.
  • Plans to continue to build ImmunoBank with additional IND filings throughout 2024.

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

Retrieved on: 
Wednesday, December 27, 2023
Patient, Safety, Immune system, SITC, UNO, Pharmaceutical industry

HAMILTON, Bermuda, Dec. 27, 2023 (GLOBE NEWSWIRE) --  Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) and a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the first cohort of 25,000 ppm single dose UNO by the Safety Review Committee with no reported dose limiting toxicities.

Key Points: 
  • The first-in-human, open-label, non-randomized Phase 1 study is being conducted in two parts: Dose Escalation and Dose Expansion.
  • The Dose Escalation consists of three UNO cohorts (25,000, 50,000 and 100,000 ppm) of three to six patients.
  • The Dose Expansion will begin once the recommended dose is determined in the Dose Escalation portion.
  • “The well tolerated administration of UNO is encouraging and the feasibility of UNO administration in patients has been demonstrated.

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, December 19, 2023
MSD, Partnership, Targets, Messenger, MTA, Biomarker, Research and development, WHO, Cancer, Vaccine, Gonorrhea, Merck & Co., Society, Research, AI, ASH, GHI, KOL, Merck, Patient, Infection, Development, Bone marrow, Melanoma, SITC, Pharmaceutical industry

On December 18, 2023, Evaxion priced a bridge financing round, expected to raise aggregate proceeds of approximately $5.3 million.

Key Points: 
  • On December 18, 2023, Evaxion priced a bridge financing round, expected to raise aggregate proceeds of approximately $5.3 million.
  • Cash burn for 2024, excluding financing activities, is expected at the level of $14 million (with Q1 cash burn being significantly higher than other quarters in 2024)
    COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provided a business update and announced its third quarter 2023 financial results.
  • A key focus for the first months has been to refine the Evaxion strategy with a strong focus on execution and value realization.
  • Evaxion announces a groundbreaking precision vaccine concept for hematological malignancies at the 65th American Society of Hematology (ASH) Annual Meeting.

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant

Retrieved on: 
Monday, December 18, 2023
Cytokine, AACR, Immunotherapy, Research, The central science, Vaccine, Molecular biology, Patent, MD, Doctor of Philosophy, Pharmacology, Biochemistry, University, Society, T cell, OTCQB, Physiology, Heat shock protein, RBS, Chemokine, SITC

The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.

Key Points: 
  • The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.
  • Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee.
  • The research underlying the allowed application was led by Dr. Narendran and his lab team (the Narendran Lab).
  • This work also portends the potential benefit of PV-10 in combination with targeted immunotherapies and antibody-drug conjugates for cancer treatment.

EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing

Retrieved on: 
Wednesday, December 13, 2023
Immunotherapy, Tumor microenvironment, Immunology, Chemistry, CMC, Lead, Therapy, CD2, Society, Control, EVOLVE, Bristol Myers Squibb, ULBP2, SITC, Vaccine

BRANFORD, Conn., Dec. 13, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current immune therapy agents, today provided a corporate and program update related to the advancement of its pipeline of first-in-category precision immuno-oncology agents. The company announced the closing of a $37 million financing round, which was supported by existing investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., along with new strategic investor Bristol Myers Squibb.

Key Points: 
  • The company announced the closing of a $37 million financing round, which was supported by existing investors including Pfizer Ventures, Solasta Ventures, and Takeda Ventures, Inc., along with new strategic investor Bristol Myers Squibb.
  • EvolveImmune intends to use the proceeds from this fundraising to support continued platform and pipeline development including the advancement of its lead multi-functional T-cell engager program, EV-104.
  • “This new capital raise comes at an exciting time for EvolveImmune,” said Stephen Bloch, M.D., chief executive officer of EvolveImmune.
  • The platform also takes advantage the company’s understanding of specific tumor cell characteristics to guide tumor antigen prioritization and program differentiation.